GIP Incretin Reporter HEK 293 Cells - GIP Bioassay

Cell line description

HEK-Blue™ GIP cells were generated by stable transfection of the human embryonic kidney HEK293 cell line with the gene encoding human GIP receptor (GIPR). In addition, a SEAP (secreted embryonic alkaline phosphatase) reporter gene under the control of a minimal promoter fused to nine cAMP response elements (CRE) was introduced. Binding of GIP or a synthetic hormone receptor agonist to the GIPR on the surface of HEK-Blue™ GIP cells triggers a signaling cascade leading to the activation of the CRE-binding Protein (CREB) pathway and the subsequent production of SEAP. This can be readily assessed in the supernatant using QUANTI‑Blue™ Solution, a SEAP detection reagent. 

HEK‑Blue™ GIP cells respond to GIP and other GIP receptor (GIPR) agonists, such as Tirzepatide and Retatrutide. They do not respond to other  G protein-coupled receptor (GPCR)-activating hormones or their analogs, including GLP-1 (glucagon-like peptide-1), glucagon, Semaglutide, or Orforglipron. HEK-Blue™ GIP cells express approximately 8,000 GIP receptors per cell, a surface receptor density consistent with physiological levels reported in the literature [1].

GIP background

The glucose-dependent insulinotropic polypeptide (GIP), also known as gastric inhibitory polypeptide, is an incretin hormone secreted by enteroendocrine K-cells of the small intestine in response to food intake. It acts via the GIP receptor (GIPR), a G protein-coupled receptor (GPCR) predominantly expressed in pancreatic β cells, adipose tissue, and the central nervous system [2]. 

Activation of GIPR triggers the activation of the G protein, which stimulates Adenylyl cyclase. This leads to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP activates Protein kinase A (PKA), which then translocates to the nucleus and phosphorylates cAMP response element binding protein (CREB). As a key transcription factor, CREB mediates many of the downstream effects of GIP, including the regulation of glucose homeostasis as well as the survival and proliferation of pancreatic β cells [3].

Upon binding to GIPR, GIP enhances glucose-dependent insulin secretion [2]. Beyond this primary effect, GIP exerts a range of pleiotropic actions, including the promotion of β cell survival and proliferation, the regulation of body weight through centrally mediated appetite suppression, and the attenuation of both peripheral and central inflammation. Emerging evidence also highlights its beneficial roles in cognitive function and bone metabolism. Consequently, alterations in GIP secretion and/or signaling are now recognized as key contributors to the pathogenesis of metabolic disorders such as diabetes and obesity [3].

The discovery of the synergistic action between GIP and GLP-1 has shed new light on the central role of GIP in metabolic regulation. Together, these hormones enhance insulin secretion more effectively than either alone, while also promoting satiety and supporting weight loss. This combined effect has sparked significant interest in therapeutic innovation, leading to the development of novel multi-agonist long-acting compounds such as Tirzepatide (Mounjaro®/Zepbound®) and Retatrutide (LY3437943) [4]. These ligands are now at the forefront of a new generation of treatments, offering transformative potential in the management of diabetes and obesity and are now being explored for other metabolic disorders, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) [4].

1. Maletti M et al, 1984. Characterization of specific receptors for gastric inhibitory polypeptide (GIP) in a hamster pancreatic beta-cell line. Endocrinology. 114(6), 2344-2350.
2. Drucker DJ, Holst JJ, 2023. The expanding incretin universe: from basic biology to clinical translation. Diabetologia. 66(10):1765-1779. 
3. Müller TD et al, 2025 Glucose-dependent insulinotropic polypeptide (GIP). Mol Metab. 95:102118.
4. Gutgesell RM, et al. 2024. Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes. Diabetes Ther. 2024 May;15(5):1069-1084.